TWI720940B - 長效型多肽及其生產和給藥的方法 - Google Patents

長效型多肽及其生產和給藥的方法 Download PDF

Info

Publication number
TWI720940B
TWI720940B TW103143380A TW103143380A TWI720940B TW I720940 B TWI720940 B TW I720940B TW 103143380 A TW103143380 A TW 103143380A TW 103143380 A TW103143380 A TW 103143380A TW I720940 B TWI720940 B TW I720940B
Authority
TW
Taiwan
Prior art keywords
ctp
another embodiment
peptide
growth hormone
terminal
Prior art date
Application number
TW103143380A
Other languages
English (en)
Chinese (zh)
Other versions
TW201536327A (zh
Inventor
富瓦 法瑞斯
烏迪 艾歐 費瑪
Original Assignee
以色列商歐科生物製品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/059,134 external-priority patent/US20140113860A1/en
Priority claimed from US14/309,496 external-priority patent/US20150038413A1/en
Application filed by 以色列商歐科生物製品有限公司 filed Critical 以色列商歐科生物製品有限公司
Publication of TW201536327A publication Critical patent/TW201536327A/zh
Application granted granted Critical
Publication of TWI720940B publication Critical patent/TWI720940B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
TW103143380A 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法 TWI720940B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/059,134 2013-10-21
US14/059,134 US20140113860A1 (en) 2006-02-03 2013-10-21 Long-acting polypeptides and methods of producing and administering same
US14/309,496 US20150038413A1 (en) 2006-02-03 2014-06-19 Long-acting polypeptides and methods of producing and administering same
US14/309,496 2014-06-19

Publications (2)

Publication Number Publication Date
TW201536327A TW201536327A (zh) 2015-10-01
TWI720940B true TWI720940B (zh) 2021-03-11

Family

ID=52992360

Family Applications (5)

Application Number Title Priority Date Filing Date
TW103143380A TWI720940B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW103143381A TW201536312A (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW110104795A TWI777407B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW111132309A TWI893324B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW103136384A TWI720939B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW103143381A TW201536312A (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW110104795A TWI777407B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW111132309A TWI893324B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法
TW103136384A TWI720939B (zh) 2013-10-21 2014-10-21 長效型多肽及其生產和給藥的方法

Country Status (21)

Country Link
EP (2) EP3763733A1 (enExample)
JP (3) JP6640720B2 (enExample)
KR (4) KR20160068969A (enExample)
CN (1) CN106163543A (enExample)
AU (3) AU2014338575B2 (enExample)
CA (1) CA2928269C (enExample)
DK (1) DK3060239T3 (enExample)
ES (1) ES2811068T3 (enExample)
FR (1) FR22C1035I2 (enExample)
HR (1) HRP20201114T1 (enExample)
HU (2) HUE050002T2 (enExample)
IL (1) IL297219B2 (enExample)
LU (1) LUC00259I2 (enExample)
MX (2) MX381148B (enExample)
NL (1) NL301170I2 (enExample)
PL (1) PL3060239T3 (enExample)
PT (1) PT3060239T (enExample)
RU (1) RU2746943C2 (enExample)
SI (1) SI3060239T1 (enExample)
TW (5) TWI720940B (enExample)
WO (1) WO2015059695A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201114T1 (hr) 2013-10-21 2020-10-30 Opko Biologics Ltd. Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CN109942717A (zh) * 2019-04-24 2019-06-28 上海延立药业有限公司 一种长效重组人促卵泡激素及其制备方法和应用
KR20230171936A (ko) * 2021-03-19 2023-12-21 화이자 인코포레이티드 지속 작용성 성장 호르몬 폴리펩타이드를 투여하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130184207A1 (en) * 2006-02-03 2013-07-18 Prolor Biotech Inc. Long-acting polypeptides and methods of producing and administering same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0374257B1 (en) 1988-05-06 1994-08-31 Toray Industries, Inc. STABLE INTERFERON $g(b) COMPOSITION
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
DE102007006189B4 (de) * 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
HRP20201114T1 (hr) 2013-10-21 2020-10-30 Opko Biologics Ltd. Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130184207A1 (en) * 2006-02-03 2013-07-18 Prolor Biotech Inc. Long-acting polypeptides and methods of producing and administering same

Also Published As

Publication number Publication date
MX2021003908A (es) 2021-06-23
DK3060239T3 (da) 2020-08-03
RU2016119565A (ru) 2018-11-02
WO2015059695A1 (en) 2015-04-30
TW201536312A (zh) 2015-10-01
PL3060239T3 (pl) 2020-11-02
EP3060239A1 (en) 2016-08-31
AU2014338575A1 (en) 2016-06-02
JP7445695B2 (ja) 2024-03-07
EP3060239A4 (en) 2017-05-31
ES2811068T3 (es) 2021-03-10
RU2021110927A3 (enExample) 2021-12-08
TWI720939B (zh) 2021-03-11
KR20160068969A (ko) 2016-06-15
JP2020073541A (ja) 2020-05-14
AU2022246472A1 (en) 2022-11-10
NL301170I1 (nl) 2022-04-29
EP3763733A1 (en) 2021-01-13
KR20210118490A (ko) 2021-09-30
IL297219B2 (en) 2024-02-01
IL297219A (en) 2022-12-01
RU2746943C2 (ru) 2021-04-22
HUS2200014I1 (hu) 2022-05-28
TW201536327A (zh) 2015-10-01
HUE050002T2 (hu) 2020-11-30
SI3060239T1 (sl) 2020-10-30
JP7051797B2 (ja) 2022-04-11
JP2022088521A (ja) 2022-06-14
LUC00259I2 (enExample) 2025-04-25
KR20220130254A (ko) 2022-09-26
AU2022246472B2 (en) 2025-08-14
KR20240110069A (ko) 2024-07-12
TWI893324B (zh) 2025-08-11
CA2928269C (en) 2023-03-14
TW202317176A (zh) 2023-05-01
RU2021110927A (ru) 2021-05-21
JP2016535015A (ja) 2016-11-10
NL301170I2 (nl) 2022-06-16
TW201536313A (zh) 2015-10-01
KR102444140B1 (ko) 2022-09-15
AU2014338575B2 (en) 2019-11-07
MX2016005227A (es) 2016-08-12
PT3060239T (pt) 2020-08-26
TW202120120A (zh) 2021-06-01
CA2928269A1 (en) 2015-04-30
FR22C1035I1 (fr) 2022-09-09
JP6640720B2 (ja) 2020-02-05
IL297219B1 (en) 2023-10-01
FR22C1035I2 (fr) 2024-02-16
AU2020200874A1 (en) 2020-02-27
CN106163543A (zh) 2016-11-23
HRP20201114T1 (hr) 2020-10-30
TWI777407B (zh) 2022-09-11
EP3060239B1 (en) 2020-05-13
RU2016119565A3 (enExample) 2019-01-22
MX381148B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
US12029780B2 (en) Long-acting polypeptides and methods of producing and administering same
JP6153930B2 (ja) 持続型成長ホルモンおよびそれを生成する方法
US8304386B2 (en) Long-acting growth hormone and methods of producing same
US20200131242A1 (en) Methods of treatment with long-acting hormone
JP7445695B2 (ja) 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法
RU2798845C2 (ru) Полипептиды длительного действия и способы их получения и введения
HK40034109A (en) Long-acting polypeptides and methods of producing and administering same
HK40008897A (en) Long-acting growth hormone and methods of producing same
US20150126444A1 (en) Long-acting polypeptides and methods of producing and administering same
HK40008897B (en) Long-acting growth hormone and methods of producing same
EA045766B1 (ru) Соматотропный гормон пролонгированного действия и способы его получения